Susquehanna International Group, LLP Madrigal Pharmaceuticals, Inc. Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$212.22 - $292.96 $3.54 Million - $4.89 Million	16,700 Added 10.86%	170,500 $36.2 Million
Q2 2024 Aug 15, 2024	SELL	$193.33 - $291.99 $34.8 Million - $52.6 Million	-180,000 Reduced 53.92%	153,800 $43.1 Million
Q1 2024 May 07, 2024	BUY	$171.37 - $283.23 $40.4 Million - $66.8 Million	236,000 Added 241.31%	333,800 $89.1 Million
Q4 2023 Feb 14, 2024	SELL	$120.4 - $237.13 $782,600 - $1.54 Million	-6,500 Reduced 6.23%	97,800 $22.6 Million
Q3 2023 Nov 14, 2023	SELL	$146.04 - $225.78 $9.11 Million - $14.1 Million	-62,400 Reduced 37.43%	104,300 $15.2 Million
Q2 2023 Aug 11, 2023	BUY	$203.88 - $312.0 $13.2 Million - $20.2 Million	64,700 Added 63.43%	166,700 $38.5 Million
Q1 2023 May 16, 2023	SELL	$231.06 - $307.08 $69.5 Million - $92.4 Million	-300,800 Reduced 74.68%	102,000 $24.7 Million
Q4 2022 Feb 14, 2023	BUY	$58.39 - $296.54 $22.1 Million - $112 Million	377,800 Added 1511.2%	402,800 $117 Million
Q3 2022 Nov 14, 2022	BUY	$60.57 - $79.51 $393,705 - $516,815	6,500 Added 35.14%	25,000 $1.63 Million

297

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.28B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.